View Post

Triple-negative breast cancer metastases in lungs contain more diverse cells than those in liver

In In The News by Barbara Jacoby

Source: American Association for the Advancement of Science From: eurekalert.org The site of breast cancer metastases dictates their clonal composition and reversible transcriptomic profile Metastatic tumors originating from notoriously aggressive triple-negative breast cancer that emerge in the lungs contain a more diverse array of cancer cells than those that arise in the liver, according to a new study in mice …

View Post

Potential Drug Target for Difficult-To-Treat Breast Cancer: RNA-Binding Proteins

In Clinical Studies News by Barbara Jacoby

By: Heather Buschman, PhD From: ucsd.edu Studies using human cell lines and tumors grown in mice provide early evidence that inhibiting RNA-binding proteins, a previously overlooked family of molecules, might provide a new approach for treating some cancers In cancer research, it’s a common goal to find something about cancer cells — some sort of molecule — that drives their …

View Post

Targeting ‘enabler cells’ to stop the spread of triple-negative breast cancer

In Clinical Studies News by Barbara Jacoby

By: Angus Liu From: fiercebiotech.com Triple-negative breast cancer is aggressive and linked to worse prognoses than other types of the disease. Now, a research team led by scientists at Georgetown University Medical Center has identified a small subset of early breast cancer cells that drives the invasive spread to other parts of the body. By using CRISPR editing and RNA sequencing, …

View Post

Natural killers: Using the body’s cells to target breast cancer

In Clinical Studies News by Barbara Jacoby

Source: Clemson Universitty From: medicalxpress.com It sounds like a plot from a Quentin Tarantino movie—something sets off natural killers and sends them on a killing spree. But instead of characters in a movie, these natural killers are part of the human immune system and their targets are breast cancer tumor cells. The triggers are fusion proteins developed by Clemson University …

View Post

Sacituzumab Govitecan for Metastatic TNBC Retains Survival Advantage Over Chemotherapy

In Clinical Studies News by Barbara Jacoby

By: Kristi Rosa From: cancernetwork.com Patients with metastatic TNBC treated with sacituzumab govitecan maintained an efficacy benefit compared with physician’s choice chemotherapy. Patients with metastatic triple-negative breast cancer (TNBC) treated with sacituzumab govitecan (Trodelvy), an antibody-drug conjugate (ADC), maintained a benefit in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) compared with physician’s choice of therapy, regardless …

View Post

Cantargia advance development of antibody CAN04 by a new clinical trial in triple negative breast cancer

In Clinical Studies News by Barbara Jacoby

Source: Cantargia AB From: prnewswire.com Cantargia AB today announced signing a Letter of Intent with the Spanish Breast Cancer Group (GEICAM) to perform a new clinical trial investigating the antibody nadunolimab (CAN04) in combination with carboplatin/gemcitabine for the treatment of patients with advanced triple negative breast cancer (TNBC). The trial will investigate the safety and efficacy of the combination in …

View Post

Black women at higher risk for triple-negative breast cancer mortality

In In The News by Barbara Jacoby

From: healio.com Black women had a significantly higher risk for death due to nonmetastatic triple-negative breast cancer than white women, according to study results published in JAMA Oncology. The difference may be partially explained by disparities in receipt of surgery and chemotherapy, researchers noted. “Black women experience a disproportional burden of poor breast cancer outcomes than white women, which is …

View Post

Datopotamab Deruxtecan Shows Encouraging Preliminary Safety, Efficacy in TNBC

In Clinical Studies News by Barbara Jacoby

By: Courtney Marabella From: onclive.com The differentiated TROP2-directed antibody-drug conjugate datopotamab deruxtecan was found to have promising antitumor activity with a manageable safety profile in heavily pretreated patients with triple-negative breast cancer. The differentiated TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (DS-1062a) was found to have promising antitumor activity with a manageable safety profile in heavily pretreated patients with triple-negative breast …

View Post

Retesting for HER2 Upon Breast Cancer Relapse May Provide New Therapeutic Opportunities

In Clinical Studies News by Barbara Jacoby

By: Kristi Rosa From: onclive.com Approximately 30% of breast cancer tumors can covert from, or to, HER2-low status, underscoring the need to retest for HER2 expression upon relapse. Approximately 30% of breast cancer tumors can covert from, or to, HER2-low status, underscoring the need to retest for HER2 expression upon relapse, according to results from a study presented during the …